Strategic Forecast for the GLP-1 Receptor Agonist Industry: Market Outlook 2025-2034

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

GLP-1 Receptor Agonist Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market size of GLP-1 receptor agonist has seen a consistent growth. The market is projected to expand from $13.58 billion in 2024 to $14.22 billion in 2025, with a compound annual growth rate (CAGR) of 4.7%. Factors contributing to the growth during the historical period include an increase in diabetes cases, clinical effectiveness, heightened patient awareness and acceptance, worldwide health initiatives, and a patient inclination towards injectable treatments.

How Will the GLP-1 Receptor Agonist Market Size Evolve and Grow by 2029?
It's projected that the GLP-1 receptor agonist market will flourish significantly in the coming years, expanding to a worth of $17.72 billion in 2029, with a compound annual growth rate (CAGR) of 5.7%. The expected growth during the projected period is the result of increasing focus on lifestyle management, rising popularity of tailored medicine approaches, broadening indications, evolution of next-generation products, and incorporation into combined therapy methods. The primary trends for the forecast period comprise the production of oral formulations, an emphasis on combination treatments, strategic alliances and partnerships, reimbursement policies and access, and patient-oriented strategies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

What Drivers Are Propelling the Growth of GLP-1 Receptor Agonist Market Forward?
The GLP-1 receptor agonist market is predicted to flourish due to the increasing occurrence of diabetes. Diabetes is a persistent disease that arises when either insufficient insulin is produced by the pancreas or the body fails to effectively use the produced insulin. Elevated blood sugar levels depict a metabolic disorder called diabetes mellitus. GLP-1 receptor agonists are utilized in diabetes treatment to induce more insulin production, therefore, aiding in blood sugar reduction. As a result, the escalating occurrence of diabetes will stimulate market growth. For example, as per the UK's Office for Health Improvement and Disparities in March 2024, from March 2022 to March 2023, there was an observed increase in the percentage of individuals with type 1 diabetes receiving all eight proposed care processes by 22%. The same increase was seen in type 2 diabetes cases by 21%, whereas the accomplishment of target HbA1c levels reached 37.9%, as per the highest ever record from the National Diabetes Audit (NDA). Consequently, the increasing occurrence of diabetes is stimulating the growth of the GLP-1 receptor agonist market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp

Which Emerging Trends Are Transforming the GLP-1 Receptor Agonist Market in 2025?
In the GLP-1 receptor agonist market, a significant trend that's witnessing an upward trajectory is the surge in product innovations. The leading players within this market niche are channeling their efforts towards pioneering inventive solutions as a route to consolidate their dominance. A case in point was in May 2022, when Eli Lilly and Company, a pharmaceutical organization in the US committed to improving lives through the production of innovative medicines, unveiled the FDA-endorsed Mounjaro, an agonist for GIP and GLP-1 receptors. This product was crafted using a solo molecule that triggers the body's receptors for the incretin hormones GIP and GLP-1. It's offered as a pen auto-injector furnished with a pre-fixed, concealed needle that spares patients the task of handling or seeing it. Additionally, it's available in six different doses.

What Are the Key Segments in the GLP-1 Receptor Agonist Market?
The GLP-1 receptor agonist market covered in this report is segmented -

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users

Subsegments:
1) By Exenatide: Byetta, Bydureon
2) By Liraglutide: Victoza, Saxenda
3) By Dulaglutide: Trulicity
4) By Lixisenatide: Adlyxin
5) By Other Drugs: Semaglutide, Tirzepatide, Others

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9631&type=smp

Who Are the Key Players Shaping the GLP-1 Receptor Agonist Market's Competitive Landscape?
Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG

What Geographic Markets Are Powering Growth in the GLP-1 Receptor Agonist Market?
North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9631

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.